{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:40:15Z","timestamp":1792813215679,"version":"4.5.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Fujian Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bcp.2026.118574","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:01:44Z","timestamp":1792796504000},"page":"118574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting coagulation factor XI\/XIa for anticoagulation therapy: from mechanism to drug development"],"prefix":"10.1016","author":[{"given":"Yang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haili","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0005","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.jtha.2025.03.026","article-title":"Direct oral anticoagulant failure in patients with venous thromboembolism-why and what next?","volume":"23","author":"Swan","year":"2025","journal-title":"J. Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.bcp.2026.118574_b0010","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(18)30356-9","article-title":"Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation","volume":"18","author":"Seiffge","year":"2019","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0020","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1161\/STROKEAHA.124.047715","article-title":"Combination Antithrombotic Therapy for Reduction of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease","volume":"56","author":"Perera","year":"2025","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.bcp.2026.118574_b0025","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1182\/blood-2018-06-820746","article-title":"Treatment of bleeding complications in patients on anticoagulant therapy","volume":"133","author":"Piran","year":"2019","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2026.118574_b0030","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jtha.2025.11.033","article-title":"Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants","volume":"24","author":"Dobbing","year":"2026","journal-title":"J. Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.bcp.2026.118574_b0035","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s40265-020-01345-5","article-title":"Prevention and treatment of bleeding with direct oral anticoagulants","volume":"80","author":"Crawley","year":"2020","journal-title":"Drugs"},{"issue":"10333","key":"10.1016\/j.bcp.2026.118574_b0040","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/S0140-6736(22)00563-3","article-title":"Making anticoagulation safer","volume":"399","author":"Gailani","year":"2022","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.bcp.2026.118574_b0045","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1093\/eurheartj\/eht013","article-title":"Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy","volume":"34","author":"Verheugt;","year":"2013","journal-title":"Eur. Heart J."},{"issue":"15","key":"10.1016\/j.bcp.2026.118574_b0050","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1182\/blood.2023020722","article-title":"Targeting factor XI and factor XIa to prevent thrombosis","volume":"143","author":"Gailani","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcp.2026.118574_b0055","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jacc.2022.11.057","article-title":"Clinical evaluation of factor XIa inhibitor drugs: JACC review topic of the week","volume":"81","author":"Harrington","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.bcp.2026.118574_b0060","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.2023020721","article-title":"Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment","volume":"143","author":"Barg","year":"2024","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bcp.2026.118574_b0065","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1182\/bloodadvances.2021005695","article-title":"Anticoagulant therapy in patients with congenital FXI deficiency","volume":"5","author":"Bravo-Perez","year":"2021","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.bcp.2026.118574_b0070","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s11239-024-02972-5","article-title":"Factor XI: structure, function and therapeutic inhibition","volume":"57","author":"Ali","year":"2024","journal-title":"J. Thromb. Thrombolysis"},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0075","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40256-025-00787-0","article-title":"Targeting factor XI for safer anticoagulation: emerging data and future directions","volume":"26","author":"Campanella","year":"2026","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1055\/a-1984-7021","article-title":"A review of FXIa inhibition as a novel target for anticoagulation","volume":"43","author":"Koulas","year":"2023","journal-title":"Hamostaseologie"},{"issue":"15","key":"10.1016\/j.bcp.2026.118574_b0085","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1182\/blood.2023020719","article-title":"Biology of factor XI","volume":"143","author":"Moellmer","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2026.118574_b0090","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40265-024-02049-w","article-title":"Therapeutic potential of FXI inhibitors: hype or hope?","volume":"84","author":"Galli","year":"2024","journal-title":"Drugs"},{"issue":"7","key":"10.1016\/j.bcp.2026.118574_b0095","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.jtha.2023.04.021","article-title":"News at XI: moving beyond factor Xa inhibitors","volume":"21","author":"Fredenburgh","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0100","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.jacc.2021.06.010","article-title":"Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week","volume":"78","author":"Hsu","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0105","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/med.21503","article-title":"Recent advances in the discovery and development of factor XI\/XIa inhibitors","volume":"38","author":"Al-Horani","year":"2018","journal-title":"Med. Res. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118574_b0110","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1161\/ATVBAHA.124.322145","article-title":"Discovery of the low-hemorrhagic antithrombotic effect of montelukast by targeting FXIa in mice","volume":"45","author":"Zhou","year":"2025","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0115","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1021\/acs.jmedchem.6b01460","article-title":"Structure-based design of macrocyclic factor XIa inhibitors: discovery of the macrocyclic amide linker","volume":"60","author":"Corte","year":"2017","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0120","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1021\/acs.jmedchem.1c00056","article-title":"Development of selective FXIa inhibitors based on cyclic peptides and their application for safe anticoagulation","volume":"64","author":"Carle","year":"2021","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bcp.2026.118574_b0125","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1021\/acs.jmedchem.2c02130","article-title":"Factor XIa inhibitors in anticoagulation therapy: recent advances and perspectives","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0130","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/jth.15716","article-title":"Revised model of the tissue factor pathway of thrombin generation: role of the feedback activation of FXI","volume":"20","author":"Lakshmanan","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0135","first-page":"75","article-title":"Roles of platelets and factor XI in the initiation of blood coagulation by thrombin","volume":"86","author":"Walsh","year":"2001","journal-title":"Thromb. Haemost."},{"issue":"12","key":"10.1016\/j.bcp.2026.118574_b0140","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/jth.12435","article-title":"Evidence for factor IX-independent roles for factor XIa in blood coagulation","volume":"11","author":"Matafonov","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.bcp.2026.118574_b0145","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2009-09-199182","article-title":"Structure and function of factor XI","volume":"115","author":"Emsley","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.118574_b0150","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1182\/blood-2015-04-641472","article-title":"FXIa and platelet polyphosphate as therapeutic targets during human blood clotting on collagen\/tissue factor surfaces under flow","volume":"126","author":"Zhu","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2026.118574_b0155","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1182\/blood-2014-10-604587","article-title":"Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor","volume":"125","author":"Puy","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.bcp.2026.118574_b0160","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1021\/acsptsci.3c00052","article-title":"Determination of the potential clinical benefits of small molecule factor XIa inhibitors in arterial thrombosis","volume":"6","author":"Wichaiyo","year":"2023","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"17","key":"10.1016\/j.bcp.2026.118574_b0165","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1182\/blood.2023022257","article-title":"Coagulation factor XI regulates endothelial cell permeability and barrier function in vitro and in vivo","volume":"144","author":"Puy","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0170","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jth.15126","article-title":"New anticoagulants: Moving beyond the direct oral anticoagulants","volume":"19","author":"Fredenburgh","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0175","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1172\/JCI575","article-title":"Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation","volume":"101","author":"Gresele","year":"1998","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.bcp.2026.118574_b0180","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1538-7836.2010.04031.x","article-title":"Coagulation factor XI as a novel target for antithrombotic treatment","volume":"8","author":"Lowenberg","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118574_b0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1538-7836.2009.03414.x","article-title":"Structural and functional features of factor XI","volume":"7 Suppl 1","author":"Gailani","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0190","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2017-07-792580","article-title":"Prochemerin cleavage by factor XIa links coagulation and inflammation","volume":"131","author":"Ge","year":"2018","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bcp.2026.118574_b0195","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.drudis.2014.05.018","article-title":"Factor XI as a target for antithrombotic therapy","volume":"19","author":"Bane","year":"2014","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0200","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1016\/j.jtha.2025.06.030","article-title":"Venous thromboembolism in patients with cancer and factor XI deficiency","volume":"23","author":"Chrysafi","year":"2025","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0205","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/ATVBAHA.123.318781","article-title":"New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors","volume":"43","author":"Chan","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.bcp.2026.118574_b0210","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bcp.2026.118574_b0215","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1111\/jth.15890","article-title":"Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis","volume":"20","author":"Presume","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.bcp.2026.118574_b0220","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0225","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/ATVBAHA.115.307034","article-title":"Coagulation factor XI promotes distal platelet activation and single platelet consumption in the bloodstream under shear flow","volume":"36","author":"Zilberman-Rudenko","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0230","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/jth.13441","article-title":"Coagulation and non-coagulation effects of thrombin","volume":"14","author":"Posma","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2026.118574_b0235","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","article-title":"Factor Xa or thrombin: is factor Xa a better target?","volume":"5","author":"Ansell","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.bcp.2026.118574_b0240","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat. Rev. Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0245","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/med.20183","article-title":"Developments in factor Xa inhibitors for the treatment of thromboembolic disorders","volume":"31","author":"Lee","year":"2011","journal-title":"Med. Res. Rev."},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/eurheartj\/ehm575","article-title":"New oral anticoagulants in atrial fibrillation","volume":"29","author":"Turpie","year":"2008","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.bcp.2026.118574_b0255","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.jtha.2025.02.025","article-title":"Anticoagulant drugs targeting factor XI\/XIa and coagulation tests: we urgently need reliable pharmacodynamic data","volume":"23","author":"Gouin-Thibault","year":"2025","journal-title":"J. Thromb. Haemost."},{"issue":"19","key":"10.1016\/j.bcp.2026.118574_b0260","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/blood-2012-12-473629","article-title":"The dimeric structure of factor XI and zymogen activation","volume":"121","author":"Geng","year":"2013","journal-title":"Blood"},{"issue":"40","key":"10.1016\/j.bcp.2026.118574_b0265","doi-asserted-by":"crossref","first-page":"15693","DOI":"10.1073\/pnas.0703080104","article-title":"Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation","volume":"104","author":"Samuel","year":"2007","journal-title":"PNAS"},{"issue":"11","key":"10.1016\/j.bcp.2026.118574_b0270","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/jth.15842","article-title":"HK is the apple of FXI's eye","volume":"20","author":"Moellmer","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jtha.2023.09.027","article-title":"High molecular weight kininogen interactions with the homologs prekallikrein and factor XI: importance to surface-induced coagulation","volume":"22","author":"Mohammed","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.bcp.2026.118574_b0280","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1046\/j.1538-7836.2003.00418.x","article-title":"Factor XI apple domains and protein dimerization","volume":"1","author":"Cheng","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.bcp.2026.118574_b0285","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/jth.14418","article-title":"Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI","volume":"17","author":"Li","year":"2019","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcp.2026.118574_b0290","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.thromres.2017.10.008","article-title":"An update on factor XI structure and function","volume":"161","author":"Mohammed","year":"2018","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.bcp.2026.118574_b0295","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/14656566.2025.2475192","article-title":"Factor XI\/XIa inhibitors: a potential solution to anticoagulation dilemmas","volume":"26","author":"Gibson","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0300","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/13543776.2020.1705783","article-title":"Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present)","volume":"30","author":"Al-Horani","year":"2020","journal-title":"Expert Opin. Ther. Pat."},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0305","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/13543776.2016.1154045","article-title":"Factor XIa inhibitors: a review of the patent literature","volume":"26","author":"Al-Horani","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0310","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1074\/jbc.M411309200","article-title":"Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions","volume":"280","author":"Jin","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.bcp.2026.118574_b0315","doi-asserted-by":"crossref","first-page":"7425","DOI":"10.1021\/acs.jmedchem.8b00173","article-title":"Factor XIa inhibitors as new anticoagulants","volume":"61","author":"Quan","year":"2018","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118574_b0320","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/13543776.2022.2026926","article-title":"Factor IX(a) inhibitors: an updated patent review (2003-present)","volume":"32","author":"Afosah","year":"2022","journal-title":"Expert Opin. Ther. Pat."},{"issue":"5","key":"10.1016\/j.bcp.2026.118574_b0325","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1021\/acs.jmedchem.1c02153","article-title":"Targeting the S2 subsite enables the structure-based discovery of novel highly selective factor XIa inhibitors","volume":"65","author":"Yao","year":"2022","journal-title":"J. Med. Chem."},{"issue":"15","key":"10.1016\/j.bcp.2026.118574_b0330","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1021\/acs.jmedchem.0c00279","article-title":"Structure-based design and preclinical characterization of selective and orally bioavailable factor XIa inhibitors: demonstrating the power of an integrated S1 protease family approach","volume":"63","author":"Lorthiois","year":"2020","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2026.118574_b0335","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1007\/s11030-024-11024-2","article-title":"Structure-based design and synthesis of novel FXIa inhibitors targeting the S2' subsite for enhanced antithrombotic efficacy","volume":"29","author":"Wu","year":"2025","journal-title":"Mol. Divers."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0340","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jtha.2022.10.001","article-title":"Allosteric modulation of exosite 1 attenuates polyphosphate-catalyzed activation of factor XI by thrombin","volume":"21","author":"Yin","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"17","key":"10.1016\/j.bcp.2026.118574_b0345","doi-asserted-by":"crossref","first-page":"12203","DOI":"10.1021\/acs.jmedchem.3c00795","article-title":"Design and preclinical characterization program toward asundexian (BAY 2433334), an oral factor XIa inhibitor for the prevention and treatment of thromboembolic disorders","volume":"66","author":"Roehrig","year":"2023","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bcp.2026.118574_b0350","doi-asserted-by":"crossref","first-page":"7226","DOI":"10.1021\/acs.jmedchem.0c00464","article-title":"Discovery of a high affinity, orally bioavailable macrocyclic FXIa inhibitor with antithrombotic activity in preclinical species","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118574_b0355","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1016\/j.jtha.2025.05.032","article-title":"DOAC-Stop reverses the anticoagulant effect of asundexian and milvexian","volume":"23","author":"Fitzpatrick","year":"2025","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0360","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.7150\/ijbs.21597","article-title":"Structural principles in the development of cyclic peptidic enzyme inhibitors","volume":"13","author":"Xu","year":"2017","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0365","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/jth.15700","article-title":"Pharmacological profile of asundexian, a novel, orally bioavailable inhibitor of factor XIa","volume":"20","author":"Heitmeier","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"23","key":"10.1016\/j.bcp.2026.118574_b0370","doi-asserted-by":"crossref","first-page":"9703","DOI":"10.1021\/acs.jmedchem.7b01171","article-title":"Discovery of a parenteral small molecule coagulation factor XIa inhibitor clinical candidate (BMS-962212)","volume":"60","author":"Pinto","year":"2017","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bcp.2026.118574_b0375","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1074\/jbc.M111.291989","article-title":"Productive recognition of factor IX by factor XIa exosites requires disulfide linkage between heavy and light chains of factor XIa","volume":"287","author":"Marcinkiewicz","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"45","key":"10.1016\/j.bcp.2026.118574_b0380","doi-asserted-by":"crossref","first-page":"38200","DOI":"10.1074\/jbc.M112.376343","article-title":"A sequential mechanism for exosite-mediated factor IX activation by factor XIa","volume":"287","author":"Geng","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2026.118574_b0385","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact Activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"353","key":"10.1016\/j.bcp.2026.118574_b0390","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf4331","article-title":"Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis","volume":"8","author":"David","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"24","key":"10.1016\/j.bcp.2026.118574_b0395","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1016\/j.jmb.2019.09.008","article-title":"Allosteric inhibition as a new mode of action for BAY 1213790, a neutralizing antibody targeting the activated form of coagulation factor XI","volume":"431","author":"Schaefer","year":"2019","journal-title":"J. Mol. Biol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118574_b0400","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1111\/jth.15815","article-title":"Nanobodies against factor XI apple 3 domain inhibit binding of factor IX and reveal a novel binding site for high molecular weight kininogen","volume":"20","author":"Bar Barroeta","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.bcp.2026.118574_b0405","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jtha.2023.12.038","article-title":"Thrombin activation of the factor XI dimer is a multistaged process for each subunit","volume":"22","author":"Bar Barroeta","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.bcp.2026.118574_b0410","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.drudis.2014.04.018","article-title":"Inhibition of Factor XI activity as a promising antithrombotic strategy","volume":"19","author":"Chen","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bcp.2026.118574_b0415","doi-asserted-by":"crossref","unstructured":"L.K. Ely, M. Lolicato, T. David, K. Lowe, Y.C. Kim, D. Samuel, P. Bessette, J.L. Garcia, T. Mikita, D.L. Minor, Jr., S.R. Coughlin, Structural Basis for Activity and Specificity of an Anticoagulant Anti-FXIa Monoclonal Antibody and a Reversal Agent, Structure 26(2) (2018) 187-198 e4.","DOI":"10.1016\/j.str.2017.12.010"},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0420","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/jth.12707","article-title":"The effect of corn trypsin inhibitor and inhibiting antibodies for FXIa and FXIIa on coagulation of plasma and whole blood","volume":"12","author":"Hansson","year":"2014","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.bcp.2026.118574_b0425","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1161\/ATVBAHA.113.301282","article-title":"Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates","volume":"33","author":"Crosby","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0430","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.kint.2024.02.024","article-title":"A Phase II randomized controlled trial evaluated antithrombotic treatment with fesomersen in patients with kidney failure on hemodialysis","volume":"106","author":"Winkelmayer","year":"2024","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0435","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.kint.2024.03.029","article-title":"Factor XI inhibition in hemodialysis patients: the safer anticoagulation?","volume":"106","author":"Stamellou","year":"2024","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0440","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jacbts.2024.12.005","article-title":"Inhibition of factor XI using RBD4059: a novel GalNAc-siRNA with potent and durable antithrombotic effects","volume":"10","author":"Liang","year":"2025","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0445","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/jth.12797","article-title":"Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity","volume":"13","author":"Chen","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"17","key":"10.1016\/j.bcp.2026.118574_b0450","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation with an inhibitor of factors XIa and XIIa during cardiopulmonary bypass","volume":"74","author":"Pireaux","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.bcp.2026.118574_b0455","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1084\/jem.20091007","article-title":"Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis","volume":"206","author":"Decrem","year":"2009","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0460","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jth.15130","article-title":"Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection","volume":"19","author":"Demoulin","year":"2021","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcp.2026.118574_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102895","article-title":"Use of factor XI\/XIa inhibitors in patients with atrial fibrillation: Current progress and future prospects","volume":"112","author":"Fan","year":"2025","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2026.118574_b0470","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jtha.2024.12.003","article-title":"New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis","volume":"23","author":"Barnes","year":"2025","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0475","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40119-024-00352-x","article-title":"Factor XI inhibitors: a new horizon in anticoagulation therapy","volume":"13","author":"Presume","year":"2024","journal-title":"Cardiol Ther"},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0480","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.3324\/haematol.2023.283682","article-title":"Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings","volume":"109","author":"Cohen","year":"2024","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0485","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1093\/cvr\/cvac091","article-title":"What to expect from drug targeting factor XI?","volume":"118","author":"Nagy","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0490","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jjcc.2025.02.013","article-title":"Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use","volume":"85","author":"Ieko","year":"2025","journal-title":"J. Cardiol."},{"issue":"25","key":"10.1016\/j.bcp.2026.118574_b0495","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1161\/CIRCULATIONAHA.122.061132","article-title":"What is the future of factor XI inhibitors?","volume":"146","author":"Weitz","year":"2022","journal-title":"Circulation"},{"issue":"6613","key":"10.1016\/j.bcp.2026.118574_b0500","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1126\/science.abn0910","article-title":"Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure","volume":"377","author":"Cao","year":"2022","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.bcp.2026.118574_b0505","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.bcp.2026.118574_b0510","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1093\/eurheartj\/ehag420","article-title":"Weekly Journal Scan: an OCEANIC wave redefines the role of factor XIa inhibition in stroke prevention","volume":"47","author":"Liuzzo","year":"2026","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.bcp.2026.118574_b0515","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2608717","article-title":"Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event","author":"Gibson","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bcp.2026.118574_b0520","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40119-024-00379-0","article-title":"Milvexian: an oral, bioavailable factor XIa inhibitor","volume":"13","author":"Parsa","year":"2024","journal-title":"Cardiol. Ther."},{"issue":"23","key":"10.1016\/j.bcp.2026.118574_b0525","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0530","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(23)00403-9","article-title":"Safety and efficacy of factor XIa inhibition with milvexian for secondary stroke prevention (AXIOMATIC-SSP): a phase 2, international, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"23","author":"Sharma","year":"2024","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0535","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.jtha.2026.02.020","article-title":"Rationale for the milvexian dosing in the phase 3 LIBREXIA program","volume":"24","author":"Weitz","year":"2026","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0540","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acs.jmedchem.1c00613","article-title":"Discovery of Milvexian, a high-affinity, orally bioavailable inhibitor of factor XIa in clinical studies for antithrombotic therapy","volume":"65","author":"Dilger","year":"2022","journal-title":"J. Med. Chem."},{"issue":"10333","key":"10.1016\/j.bcp.2026.118574_b0545","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"10357","key":"10.1016\/j.bcp.2026.118574_b0550","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(22)01588-4","article-title":"Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"400","author":"Shoamanesh","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.bcp.2026.118574_b0555","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1161\/CIRCULATIONAHA.122.061612","article-title":"Phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes after acute myocardial infarction","volume":"146","author":"Rao","year":"2022","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.bcp.2026.118574_b0560","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1111\/jth.15439","article-title":"First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa","volume":"19","author":"Thomas","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0565","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamacardio.2025.0277","article-title":"Asundexian or apixaban in patients with atrial fibrillation according to prior oral anticoagulant use: a subgroup analysis of the OCEANIC-AF randomized clinical trial","volume":"10","author":"Alexander","year":"2025","journal-title":"JAMA Cardiol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118574_b0570","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0575","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.bcp.2026.118574_b0580","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1001\/jamacardio.2025.3393","article-title":"Safety of factor XI inhibition with abelacimab in atrial fibrillation by kidney function: a prespecified analysis of the AZALEA-TIMI 71 randomized clinical trial","volume":"10","author":"Patel","year":"2025","journal-title":"JAMA Cardiol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0585","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"J. Am. Med. Assoc."},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0590","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41591-023-02794-7","article-title":"Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial","volume":"30","author":"Weitz","year":"2024","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.bcp.2026.118574_b0595","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bcp.2026.118574_b0600","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/ATVBAHA.119.312459","article-title":"AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa","volume":"39","author":"Chan","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0605","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"Buller","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bcp.2026.118574_b0610","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ekir.2021.11.011","article-title":"Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI(Rx) in Patients With ESRD","volume":"7","author":"Walsh","year":"2022","journal-title":"Kidney Int. Rep."},{"issue":"8","key":"10.1016\/j.bcp.2026.118574_b0615","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/psp4.12663","article-title":"PK\/PD modeling of FXI antisense oligonucleotides to bridge the dose-FXI activity relation from healthy volunteers to end-stage renal disease patients","volume":"10","author":"Willmann","year":"2021","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"12_Supplement","key":"10.1016\/j.bcp.2026.118574_b0620","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/S0735-1097(25)02863-3","article-title":"A phase 1, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SRSD107 in healthy adult subjects","volume":"85","author":"Li","year":"2025","journal-title":"JACC"},{"key":"10.1016\/j.bcp.2026.118574_b0625","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2024-203718","article-title":"A Phase 1, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered SRSD107 in healthy subjects","volume":"144","author":"Yue","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bcp.2026.118574_b0630","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/ATVBAHA.109.197178","article-title":"Inhibition of factor XIa as a new approach to anticoagulation","volume":"30","author":"Schumacher","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118574_b0635","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1161\/CIRCULATIONAHA.124.070278","article-title":"Association of coagulation factor XI level with cardiovascular events and cardiac function in community-dwelling adults: from ARIC and CHS","volume":"151","author":"Ji","year":"2025","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.bcp.2026.118574_b0640","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1002\/ctm2.1144","article-title":"Coagulation factor with potential for the treatment of heart failure","volume":"12","author":"Cao","year":"2022","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0645","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jtha.2023.09.015","article-title":"Effect of factor XI inhibition on tumor cell-induced coagulation activation","volume":"22","author":"Mader","year":"2024","journal-title":"J. Thromb. Haemost."},{"issue":"375","key":"10.1016\/j.bcp.2026.118574_b0650","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah4923","article-title":"Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension","volume":"9","author":"Kossmann","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"Supplement_1","key":"10.1016\/j.bcp.2026.118574_b0655","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf784.1874","article-title":"FXI levels are related to endothelial function and endothelial activation biomarkers in patients with recent acute coronary syndrome","volume":"46","author":"Nilsson","year":"2025","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.bcp.2026.118574_b0660","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.bcp.2026.118574_b0665","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s11658-026-00862-7","article-title":"Bannakunin: a dual-target Kunitz inhibitor bridging anticoagulation (FXa\/XIIa) and anti-platelet (alpha2beta1\/P2Y12) pathways","volume":"31","author":"He","year":"2026","journal-title":"Cell. Mol. Biol. Lett."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226009172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226009172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:43:45Z","timestamp":1792809825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226009172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":133,"alternative-id":["S0006295226009172"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118574","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting coagulation factor XI\/XIa for anticoagulation therapy: from mechanism to drug development","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118574"}}